Syngene International posts Q4 FY25 consolidated profit at Rs. 183.3 Cr

Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time

Carbogen Amcis Shanghai site receives drug manufacturing license from Chinese NMPA

Biocon posts Q3 FY25 PAT at Rs. 25 Cr

The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars

Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr

Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore

Carbogen Amcis successfully completed Swissmedic inspection of its Vionnaz facility

The site’s GMP Certification has been successfully renewed

NABH integrates FOGSI’S maternal health standards across its certification programs

The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs

SK pharmteco invests US$ 260 million to expand global small molecule, peptide production

Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong

India reaffirms commitment to social determinants of health at UNGA

India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting

Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr

Reported profit after tax declined 19% year-on-year to Rs 76 crores

Merck starts commercial production of first GMP-compliant manufacturing line for cell culture media in China

€ 6.6 million investment at Nantong site expands production capabilities for cell culture media